A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients (ALS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00786032 |
Recruitment Status :
Completed
First Posted : November 5, 2008
Results First Posted : January 8, 2015
Last Update Posted : January 8, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
ALS (Amyotrophic Lateral Sclerosis) | Device: BCI Device |

Study Type : | Observational |
Actual Enrollment : | 27 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Cooperative Studies Program (CSP) #567 - A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients |
Study Start Date : | September 2011 |
Actual Primary Completion Date : | June 2013 |
Actual Study Completion Date : | August 2014 |

Group/Cohort | Intervention/treatment |
---|---|
BCI Device
All participants will use the BCI System as a means of communication.
|
Device: BCI Device
A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
Other Name: Brain Computer Interface Device (BCI) |
- BCI System Usage by the ALS Patient [ Time Frame: Up to 18 months ]This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by total time.
- BCI System Usage by the ALS Patient [ Time Frame: Up to 18 months ]This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by time per application.
- BCI System Usage by the ALS Patient [ Time Frame: Up to 18 months ]This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by accuracy. Accuracy rate - The proportion of correct selections made during the daily calibration period of "copy spelling." Copy spelling data refers to data collected while the patient attends to and selects specific predefined characters, this allows the data to be coded properly (e.g., THE QUICK BROWN FOX JUMPS OVER THE LAZY DOG). Copy spelling data is used for calibration and will be collected at least 2x/week, and may be collected more frequently if unstable performance could be improved by more frequent calibration runs. The independent-use periods of the 14 independent users was totaled by days. Of these days, BCI use was not possible for days (i.e. hiatus days) due to hospitalization, illness, home construction, travel, or BCI system assistant (SA) absence. Over these days, copy-spelling accuracy was averaged.
- BCI System Usage by the ALS Patient [ Time Frame: Up to 18 months ]This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by selection rate. Accuracy rate - The proportion of correct selections made during the daily calibration period of "copy spelling." Copy spelling data refers to data collected while the patient attends to and selects specific predefined characters, this allows the data to be coded properly (e.g, THE QUICK BROWN FOX JUMPS OVER THE LAZY DOG). Copy spelling data is used for calibration and will be collected at least 2x/week, and may be collected more frequently if unstable performance could be improved by more frequent calibration runs. The number of selections/min for the BCI applications was averaged across users.
- BCI Usage by and Impact on the ALS Patient [ Time Frame: Up to 18 months ]At three-month intervals, BCI use will be summarized. On a daily basis the BCI will record the total of number of selections made in copy spelling mode. Copy spelling mode is used for system calibration. Participants are expected to indicate that the burden associated with BCI use is inconsequential to the benefit derived from using the BCI. This will be assessed by the McGill Quality of Life (MQOL) at each visit.
- Time of BCI Impact on the Significant Other and Systems Operator [ Time Frame: Up to 18 months ]The quality of life of the significant other, caregiver and system operator will be measured using the Caregiver Burden Assessment at visits. At three month intervals, the significant other, caregiver and system operator will be asked to estimate how much time they spend on the following tasks per day in minutes: BCI System setup ( placing the electrode cap and initiating system operation), BCI System cleanup, and BCI System maintenance (removing cap).
- Facility Support Speed of Solution [ Time Frame: Up to 18 months ]This study will look at how the technical problems of the BCI are supported by the facility through analyzing the speed of solution.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 79 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion and Exclusion Criteria
- Subject will be a veteran with El Escorial "Lab Supported Probable" or more definite diagnosis of ALS.
- Subject will have lost the ability to communicate either verbally or in writing (item 1 or item 4 on the ALS Functional Rating Scale-Revised (ALSFRS-R) score of 0, Appendix A) .
- Subject will be an adult (age >18).
- Subject will be living at home.
- Subject will be living within 100 miles of the participating study site.
- Subject will have corrected visual acuity of at least 20/80.
- Subject will have the ability to read and understand 6th grade English text on a computer screen.
- Subject will be able to indicate willingness and understanding of the consent form (using their existing method of communication).
- Subject will be able to identify one significant other.
- Subject will identify one system operator (person that agrees to be trained and set up the BCI). This person can be the significant other.
- Subject will be able to communicate non-verbally with their significant other, caregiver and system operator, and with study personnel.
- Significant other, caregiver and system operator will be able to indicate willingness and understanding of the consent form, be adults (age> 18) and expect to be with the subject for at least one year.
- Subject, significant other, caregiver and system operator will have life expectancy of at least one year.
- In the opinion of the BCI installation team, the home environment is physically and technologically conducive to BCI operation and use.
- Subject will demonstrate during the screening phase sufficient EEG interaction for the BCI to operate, i.e. classification rate of 70%. Classification rate is defined as the proportion of correct selections made during the daily calibration period of "copy spelling." Copy spelling data refers to data collected while the patient attends to and selects specific predefined characters.
- Significant other, caregiver and system operator will demonstrate during the screening phase sufficient skill to manage the daily set-up and routine operations needed for the subject's basic operation of the BCI.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00786032
United States, Connecticut | |
VA Connecticut Healthcare System West Haven Campus, West Haven, CT | |
West Haven, Connecticut, United States, 06516 | |
United States, New York | |
Albany VA Medical Center Samuel S. Stratton, Albany, NY | |
Albany, New York, United States, 12208 | |
United States, North Carolina | |
Durham VA Medical Center, Durham, NC | |
Durham, North Carolina, United States, 27705 | |
United States, Ohio | |
VA Medical Center, Cleveland | |
Cleveland, Ohio, United States, 44106 | |
United States, Rhode Island | |
Providence VA Medical Center, Providence, RI | |
Providence, Rhode Island, United States, 02908 |
Study Chair: | Robert Ruff, MD PhD | VA Medical Center, Cleveland |
Responsible Party: | US Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00786032 |
Other Study ID Numbers: |
567 |
First Posted: | November 5, 2008 Key Record Dates |
Results First Posted: | January 8, 2015 |
Last Update Posted: | January 8, 2015 |
Last Verified: | January 2015 |
Amyotrophic Lateral Sclerosis Brain Computer Interface (BCI) Lou Gehrig's disease |
Motor Neuron Disease Amyotrophic Lateral Sclerosis Sclerosis Pathologic Processes Neurodegenerative Diseases Nervous System Diseases |
Neuromuscular Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases |